Cedarlane › Reagents › Cedarlane Manufactured › Reagents For Human › Miscellaneous Antibodies › C3/C3b/iC3b › 7C12

7C12

Description

Cedarlane’s anti-Human C3/C3b/iC3b monoclonal antibody specifically binds human C3 as well as the breakdown products C3b and iC3b. C3 is the most abundant complement protein in serum. C3 and its cleavage products, C3a and C3b, play a central role in the complement activation cascade. C3b forms an integral part of the C3 and C5 convertases as it promotes complement activation and the subsequent formation of the membrane attack complex. C3a possesses anaphylatoxic as well as various immunoregulatory properties.

Also, C3 has been implicated in developmental and non-imflammatory process such as hematopoiesis, skeletal and vascular development and reproduction.

Cedarlane’s CL7637 (clone: 1H8) and CL7636 (clone: 7C12) recognize separate, non-overlapping epitopes on C3 fragments. Clone 7C12 is suitable for use in Flow Cytometry and ELISA.
______________________________________________________________________________________________________

Flow Cytometry Analysis
Balb/c mouse thymocytes incubated with rabbit anti-mouse T cells and then incubated with fresh human serum were stained with anti-C3/C3b/iC3b (clone: 7C12) (filled histogram) or mouse IgG1 isotype control (open histogram).


	Product Name: Anti-Human C3/C3b/iC3b, Purified, (clone: 7C12) (Mouse IgG1) Code: CL7636AP Supplier: Cedarlane Size: 250ug	Unit Price: $558.00 CDN
	Product Name: Anti-Human C3/C3b/iC3b, Biotin, (clone: 7C12) (Mouse IgG1) Code: CL7636B Supplier: Cedarlane Size: 100ug	Unit Price: $318.00 CDN
	Product Name: Anti-Human C3/C3b/iC3b, FITC, (clone: 7C12) (Mouse IgG1) Code: CL7636F Supplier: Cedarlane Size: 100ug	Unit Price: $365.00 CDN
	Product Name: Anti-Human C3/C3b/iC3b, PE, (clone: 7C12) (Mouse IgG1) Code: CL7636PE Supplier: Cedarlane Size: 50ug	Unit Price: $328.00 CDN

References
1) Kennedy AD, Solga MD, Schuman TA, Chi AW, Lindorfer MA, Sutherland WM, Foley PL, Taylor RP. (2003) An anti-C3b(i) mAb enhances complement activation, C3b(i) deposition, and killing of CD20+ cells by rituximab. Blood. 101(3):1071-9.

2) Beurskens FJ, Lindorfer MA, Farooqui M, Beum PV, Engelberts P, Mackus WJ, Parren P, Wiestner A, Taylor RP. (2012) Exhaustion of Cytotoxic Effector Systems May Limit Monoclonal Antibody-Based Immunotherapy in Cancer Patients. J Immunol. 188(7):3532-41.

3) Kennedy AD, Beum PV, Solga MD, DiLillo DJ, Lindorfer MA, Hess CE, Densmore JJ, Williams ME, Taylor RP. (2004) Rituximab infusion promotes rapid complement depletion and acute CD20 loss in chronic lymphocytic leukemia. J Immunol. 172(5):3280-8.

4) Lindorfer MA, Pawluczkowycz AW, Peek EM, Hickman K, Taylor RP, Parker CJ. (2010) A novel approach to preventing the hemolysis of paroxysmal nocturnal hemoglobinuria: both complement-mediated cytolysis and C3 deposition are blocked by a monoclonal antibody specific for the alternative pathway of complement. Blood. 115(11):2283-91.

5) Tosic L, Sutherland WM, Kurek J, Edberg JC, Taylor RP. (1989) Preparation of monoclonal antibodies to C3b by immunization with C3b(i)-sepharose. J Immunol Methods. 120(2):241-9.